Europe
MorphoSys AG andI-Mab Biopharma announced that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.
Privately-held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.
Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases.
As part of new strategy, the cluster continues to act as an innovation driver both nationally and locally
Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets
The Finnish Red Cross Blood Service offers free blood type tattoos to blood donors. The campaign raises interest towards blood donation and dismantles antiquated misconceptions around tattoos and blood donation.
labfolder is the first company amongst electronic laboratory notebook (ELN) and laboratory information management (LIMS) software vendors to announce its highly-ranked Net Promoter Score® (NPS®).
PRESS RELEASES